Evidence map›Paper›PMID 26704439›Full record

ReviewThe Lancet. Neurology2016

Accelerating stem cell trials for Alzheimer's disease.

Joshua G Hunsberger, Mahendra Rao, Joanne Kurtzberg, Jeff W M Bulte, Anthony Atala, Frank M LaFerla, Henry T Greely, Akira Sawa, Sam Gandy, Lon S Schneider and 1 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview.International journal of molecular sciences · 2021
    Review
  20. Role of Hyperglycemia in the Senescence of Mesenchymal Stem Cells.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Joshua G HunsbergerWake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA.
Mahendra RaoNew York Stem Cell Foundation, New York, NY, USA.
Joanne KurtzbergRobertson Clinical and Translational Cell Therapy Program, Duke University Medical Center, Durham, NC, USA.
Jeff W M BulteDepartment of Radiology and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anthony AtalaWake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA.
Frank M LaFerlaInstitute for Memory Impairment and Neurological Disorders, University of California-Irvine, Irvine, CA, USA.
Henry T GreelyCenter for Law and the Biosciences, Stanford University, Stanford, CA, USA.
Akira SawaDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sam GandyCenter for Cognitive Health and National Football League Neurological Care, Icahn School of Medicine at Mount Sinai, New York, NY, USA; James J Peters VA Medical Center, Bronx, NY, USA.
Lon S SchneiderAlzheimer's Disease Research Center, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
P Murali DoraiswamyDuke Institute for Brain Sciences, Duke University, Durham, NC, USA; Psychiatry Department, Duke University, Durham, NC, USA. Electronic address: murali.doraiswamy@duke.edu.

Funding

Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
MR Tracking of Magnetically Labeled Stem Cells in CNSR01NS045062 · NINDS · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2003 to 2013
$4.4M
Generation and Characterization of Alzheimer Brain CellsRF1AG042965 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GANDY, SAMUEL E., NOGGLE, SCOTT ALLEN · 2012 to 2012
$516k
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering CompoundI01RX000684 · VA · JAMES J PETERS VA MEDICAL CENTER · PI GANDY, SAMUEL E. · 2014 to 2017
–
NIA NIH HHS P30 AG066514NIA NIH HHS RF1 AG042965NINDS NIH HHS R01 NS045062RRD VA I01 RX000684
6 · The paper itself

Abstract

At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.

Indexed as

Clinical Trials as TopicInduced Pluripotent Stem CellsMesenchymal Stem Cell TransplantationAlzheimer DiseaseHumans

Identifiers

PMID26704439
PMCPMC13261700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.